Talk:InNexus Biotechnology

This article is rated Start-class on Wikipedia's content assessment scale.
It is of interest to the following WikiProjects:

Companies Mid‑importance

This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles

Mid This article has been rated as Mid-importance on the project's importance scale.

WikiProject Companies To-do:

Here are some tasks awaiting attention:

Article requests : Wikipedia:Requested articles/Business and economics/Companies
Assess : Category:Unassessed company articles
Copyedit : Category:Company articles needing attention
Infobox : Category:Company articles needing infoboxes
Maintain : Portal:Companies
Stubs : Help expand stub articles located at Category:Company stubs
Other :
- Tag company articles with the {{portal|Companies}} template
- Tag company talk pages with the {{WikiProject Companies}} project banner
- Answer requests for comments

According to the Wikipedia page on Notability, "an organization is generally considered notable if it has been the subject of coverage in reliable, independent secondary sources." InNexus was named to the Toronto Stock Exchange Top 50 in 2007, which selects the top 10 companies in 5 different industries. Thus, InNexus was named in the top 10 of its industry group by the Toronto Stock Exchange.

InNexus was one of a select group of companies allowed to operate on the Mayo Clinic campus in Scottsdale, Arizona. Such collaboration with the Mayo Clinic is unprecedented. This was highlighted in the Arizona Republic Newspaper.

InNexus is not a large company and, the Author concedes, has not yet achieved the level of interest as its largest competitor, Genentech. But, as the Wikipedia page on Notability states, "smaller organizations can be notable, just as individuals can be notable, and arbitrary standards should not be used to create a bias favoring larger organizations."

The Author respectfully asserts that recognition by the TSX and the Arizona Republic should be viewed as being sufficiently reliable and independent secondary sources for purposes of meeting the subjective standard of notability and allow continued publication of the InNexus Biotechnology Inc. page.Esqx (talk) 05:51, 3 March 2008 (UTC)[reply]

A few more good references would help prove your point. I suggest news articles from major newspapers (online articles are fine, in fact better, as anyone can easily go to them to verify the article). By the way, adding more than one link to the company (especially to its products page) is almost considered to be spamming/blatent advertising. Remember Wikipedia is not a place to try to sell/promote your products. Lastly, remember to sign your posts with ~~~~ Thanks Ejay (talk) 05:41, 3 March 2008 (UTC)[reply]

Thanks Ejay. Please keep in mind that the field of monoclonal antibodies is a niche industry and rarely - almost never - makes headlines in major or national publications or papers. There are several highly respected trade publications with articles highlighting the work being done by this company. I will update the Reference page with these articles, in furtherance of making the case for notability.Esqx (talk) 05:52, 3 March 2008 (UTC)[reply]

I see you've put in some more references, so I'm downgrading it from a speedy deletion to a possibly non-notable company. If you can find a specific URL direct to the referenced article it would be better than just a name and a link to the homepage of the external site. The references as they are don't yet make it notable enough, but I'll leave it be and see what others think. Thanks for your contributions. Ejay (talk) 08:34, 3 March 2008 (UTC)[reply]

I will also update the article to clarify a position of notability. Thanks Ejay.Esqx (talk) 18:01, 3 March 2008 (UTC)[reply]